Exelixis, Inc.

Garth Joseph McGrath

Michael R Costa

David Andrew Ruddy

Timothy S Heuer

George Ross Francis

Kim Lickteig

Daniel Tim Curtis

Michael Christopher Ellis

Sharmon Monique Nicoll

Human MARK genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of MARK are provided.

Marks as modifers of the PTEN pathway and methods of use

The invention provides methods and compositions relating to pen polypeptides having pen-specific structure and activity, related polynucleotides and modulators of pen function. The invention provides isolated pen hybridization probes and primers capable of specifically hybridizing with natural pen genes, pen-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis (e.g. genetic hybridization screens for pen transcripts), therapy (e.g. pen inhibitors to modulate APP processing) and in the biopharmaceutical industry (e.g. as immunogens, reagents for screening chemical libraries for lead pharmacological agents, etc.).

Presenilin enhancers assays

Growing community of inventors

San Rafael, CA, United States of America

Garth Joseph McGrath